stockrow
Saturday 7 November 2026
Export CBUS’s income statement to Excel — free account
Cibus, Inc.
CBUS Healthcare Biotechnology
Cibus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, down 14.6% from fiscal 2024.
- Revenue
- +6.54%
- EPS
- +52.5%
- Free cash flow
- +31.6%
- Total debt
- −62.1%
Quarter to June 2026, against a year earlier
1.17
0.03
+2.63%
Follow CBUS
Alert me
Cibus, Inc. (CBUS) P/E ratio
Cibus, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 38 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CBUS Cibus, Inc. | n/m |
| EQ Equillium, Inc. compare | n/m |
| PLYX Polaryx Therapeutics, Inc. compare | n/m |
| SEER Seer, Inc. compare | n/m |
| VTVT vTv Therapeutics Inc. compare | n/m |
| MIST Milestone Pharmaceuticals Inc. compare | n/m |
| RLYB Rallybio Corporation compare | 3.3× |
| ICCC ImmuCell Corporation compare | 117× |
| RTSN Retension Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)